My ePortfolio Register   

Expert insight: Managing neutropenia in breast cancer patients

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 23.01.18
Views: 575
Rating:

Dr Matti Aapro and Prof Hope Rugo

Dr Matti Aapro, a medical oncologist from the from the FMH Oncologie-Hématologie, Genolier, Switzerland, chaired a discussion at the 10th Breast, Gynaecological & Immunooncology International Cancer Conference (BGICC) in Cario, Egypt, alongside Professor Hope Rugo.

Dr Aapro and Professor Rugo discussed the use of Granulocyte-Colony Stimulating Factor (G-CSF) in breast cancer management, and the various methods used to reduce chemotherapy-induced neutropenia. The use of growth factor biosimilars, particularly in the U.S.A, and how they have been adopted into clinical practice was the first topic of conversation. They then spoke about chemotherapy dosing, in combination with growth factors, in patients who have neutropenia to ensure that the regime was tolerable to avoid delaying or missing the treatment schedule.

Dr Aapro and Professor Rugo then discussed neutropenia in the setting of CDK 4/6 inhibitors, and why the origin of neutropenia is difference with this class of drug due to its mechanism of action, and concluded the discussion by looking at long-acting single vs daily short acting injectables of growth factors, and the pros and cons associated with each e.g. cost management and adverse event control.

 

Related videos

follow us



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence